BLCO

Bausch + Lomb Corp

Add to Watchlist

Advanced Chart

10.510

-3.210(-23.400%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

11.880

Open

11.700

VWAP

11.05

Vol

873.41K

Mkt Cap

4.85B

Low

10.450

Amount

9.65M

EV/EBITDA(TTM)

14.67

Total Shares

351.48M

9.38B

EV/OCF(TTM)

40.42

P/S(TTM)

1.00

Bausch + Lomb Corporation is a Canada-based global eye health company. The Company’s Vision Care segment includes both a contact lens business and a consumer eye care business that consists of contact lens care products, over the counter (OTC) eye drops and eye vitamins. The Company’s Ophthalmic Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Its Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. The Company’s brands include PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, and many more.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q1

FY2025Q2

FY2025Q3

1.15B

+4.68%

0.021

-70.14%

1.26B

+3.8%

0.150

+15.47%

1.25B

+4.42%

0.189

+11.28%

Estimates Revision

The market is revising Downward the revenue expectations for Bausch + Lomb Corporation (BLCO) for FY2025, with the revenue forecasts being adjusted by -0.56% over the past three months. During the same period, the stock price has changed by -40.45%.

Revenue Estimates for FY2025

Revise Downward

-0.56%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-17.75%

In Past 3 Month

Stock Price

Go Down

-40.45%

In Past 3 Month

10 Analyst Rating

69.17% Upside

Wall Street analysts forecast BLCO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLCO is 17.78 USD with a low forecast of 15.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

6 Hold

1 Sell

Hold

69.17% Upside

Current: 10.510

Low

15.00

Averages

17.78

High

22.00

69.17% Upside

Current: 10.510

Low

15.00

Averages

17.78

High

22.00

Needham

David Saxon

Hold

Reiterates

n/a

2025-04-24

Reason

Needham

David Saxon

Price Target

n/a

2025-04-24

Reiterates

Hold

Reason

RBC Capital

Douglas Miehm

Buy

Maintains

$18 → $17

2025-04-04

Reason

RBC Capital

Douglas Miehm

Price Target

$18 → $17

2025-04-04

Maintains

Buy

Reason

After Bausch + Lomb announced a voluntary recall of its enVista intraocular lenses, RBC Capital says talks with management indicated that it remains too early to determine the financial impact. However, the firm's view is the event may lead to a charge in Q1 and a negative impact on surgery group operations until the products are returned to the market, based on similar recalls that have occurred at other companies. The current stock price decline of 6% reflects a market cap erosion of about $330M, which is higher than the $184M enterprise value that RBC ascribes to the entire surgical segment, notes the analyst, who views the stock price reaction as "likely overdone." RBC has an Outperform rating and $18 price target on B+L shares.

Stifel

Tom Stephan

Hold

Maintains

$17 → $15

2025-04-03

Reason

Stifel

Tom Stephan

Price Target

$17 → $15

2025-04-03

Maintains

Hold

Reason

Stifel lowered the firm's price target on Bausch + Lomb to $15 from $17 and keeps a Hold rating on the shares. Following last week's intraocular lense recall, the firm surveyed 54 ophthalmologists to assess the impact on B+L and broader market implications, telling investors that the survey findings were "less negative than anticipated" as a greater-than-expected proportion of doctors plan to resume using the recalled IOLs once available.

Wells Fargo

Larry Biegelsen

Buy

Hold

Downgrades

$24 → $15

2025-03-28

Reason

Wells Fargo

Larry Biegelsen

Price Target

$24 → $15

2025-03-28

Downgrades

Buy

Hold

Reason

Wells Fargo downgraded Bausch + Lomb to Equal Weight from Overweight with a price target of $15, down from $24.

HC Wainwright & Co.

Yi Chen

Strong Buy

Maintains

$23 → $20

2025-02-21

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$23 → $20

2025-02-21

Maintains

Strong Buy

Reason

BofA lowered the firm's price target on Bausch + Lomb (BLCO) to $17 from $18 and keeps an Underperform rating on the shares. 2025 guidance, particularly EBITDA, likely disappointed investors even though B+L signaled lower expectations in early January, notes the analyst. The firm continues to believe the stock upside is limited until investors get more visibility into Bausch + Lomb's separation from Bausch Health (BHC), the analyst added.

Needham

David Saxon

Hold

Reiterates

n/a

2025-02-20

Reason

Needham

David Saxon

Price Target

n/a

2025-02-20

Reiterates

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Bausch + Lomb Corp (BLCO.N) is 21.64, compared to its 5-year average forward P/E of 21.83. For a more detailed relative valuation and DCF analysis to assess Bausch + Lomb Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

21.83

Current PE

21.64

Overvalued PE

25.99

Undervalued PE

17.67

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

10.70

Current EV/EBITDA

10.33

Overvalued EV/EBITDA

11.48

Undervalued EV/EBITDA

9.92

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

1.33

Current PS

0.97

Overvalued PS

1.51

Undervalued PS

1.14

Financials

Annual

Quarterly

FY2024Q4

YoY :

+9.12%

1.28B

Total Revenue

FY2024Q4

YoY :

+19.44%

86.00M

Operating Profit

FY2024Q4

YoY :

-96.08%

-2.00M

Net Income after Tax

FY2024Q4

YoY :

-93.33%

-0.01

EPS - Diluted

FY2024Q4

YoY :

+1.45%

-70.00M

Free Cash Flow

FY2024Q4

YoY :

+3.10%

55.55

Gross Profit Margin - %

FY2024Q4

YoY :

-74.27%

-1.23

FCF Margin - %

FY2024Q4

YoY :

-96.32%

-0.16

Net Margin - %

FY2024Q4

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

2.6M

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

7.1M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

BLCO News & Events

Events Timeline

2025-04-30 (ET)

2025-04-30

07:12:29

New

Bausch + Lomb raises FY25 revenue view to $5B-$5.1B from $4.95B-$5.05B

2025-04-30

06:59:28

Bausch + Lomb reports Q1 adjusted EPS (7c), consensus 2c

2025-03-27 (ET)

2025-03-27

15:26:40

Bausch + Lomb price reaction to recall 'likely overdone,' says RBC Capital

News

2.0

04-28Benzinga

Eagle Financial Services, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session

5.0

04-22WSJ

Bausch Health Learns Icahn Has 34% Economic Interest in Shares

2.0

04-21Newsfilter

Bausch + Lomb Reports More Than 100 Million Units of Contacts Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs